WithdrawnPhase 2

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

Stopped: Funding not acquired

United States0Started 2019-01

Plain-language summary

This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on study.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Severe vestibular migraine (VM) Exclusion Criteria: * Neurologic or otologic disease other than VM * Psychiatric illness requiring medication * Medical illness including cancer, coronary artery or cerebrovascular disease * Known allergy to one of the test medications * Contraindication to use of one of the test medications - asthma, symptomatic hypotension, history of seizures * Taking migraine prophylactic medication or vestibular suppressants. * Pregnant or breast feeding women

What they're measuring

Change in Dizziness Handicap Score

Timeframe: 14 weeks

Trial details

NCT IDNCT03578354

SponsorMassachusetts Eye and Ear Infirmary

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01

View on ClinicalTrials.gov More Vestibular Migraine trials